Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2012 Results
Date:5/8/2012

and administrative (G&A) expenses are expected to be between $13.0 and $15.0 million.  This compares to $11.5 million in 2011 and includes approximately $2.0 to $4.0 million in commercial expenses for pre-launch preparation for tasimelteon in the treatment of Non-24.  G&A expenses include approximately $3.0 million of stock based compensation (SBC).  Excluding SBC, G&A expenses are expected to be between $10.0 and $12.0 million.
  • Research and development (R&D) expenses are expected to be between $42.0 and $47.0 million.  This compares to $29.0 million in 2011.  The increase of $13 to $18 million over 2011 reflects our ongoing investment in the development of tasimelteon for Non-24 and MDD.  R&D expenses include approximately $2.5 million of SBC.  Excluding SBC, R&D expenses are expected to be between $39.5 and $44.5 million. 
  • Total GAAP operating expenses are expected to be between $57.0 and $64.0 million.  This includes Fanapt® cost of sales of $1.5 million related to amortization of an intangible asset and $5.0 to $6.0 million of SBC.
  • Full year change in cash is expected to be between $45.0 and $50.0 million. 
  • The tables at the end of this press release include a reconciliation of GAAP to non-GAAP expected G&A expenses and R&D expenses. An explanation of these measures is also included below under the heading "Use of Non-GAAP Financial Measures."

    CONFERENCE CALLVanda has scheduled a conference call for today, Tuesday, May 8, 2012, at 10:00 AM ET.  During the call, Vanda's management will discuss the first quarter 2012 results and other corporate activities.  Investors can call 866-314-4865 (domestic) and 617-213-8050 (international) and use passcode 62288061.  A replay of the call will be available beginning Tuesday, May 8, 2012 at 12:00 PM ET and will be accessible until Tuesday, May 15, 2012, at 5:00 PM ET. 
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
    (Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
    (Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
    Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
    ... 16, 2012 /PRNewswire-iReach/ -- Chronic pain is ... causes of persistent, debilitating back pain. Chicago resident Pedro ... livelihood and soured his outlook on life. After taking ... he finally found relief with non-surgical treatment at the ...
    ...  Rubicon Genomics, Inc., a leader in the development ... the performance and capabilities of DNA and RNA ... announced the launch of the first product in ... designed and optimized for next generation sequencing (NGS).  ...
    Cached Medicine Technology:The Illinois Back Institute Helps Patient Beat Debilitating Back Pain 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 3
    (Date:7/23/2014)... (PRWEB) July 23, 2014 “Unlike most ... focus on developing your own unique gifts, talents and ... and clichéd sales verbiage, “says Ja Marr Brown. ... Sales Story?" which chronicles Brown’s transformation from nearly getting ... of The Year, winning every sales contest offered and ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 The ... ratified today a robust trial for a defined ... of risk adjusting relevant quality measures for sociodemographic ... NQF policy.     , Sociodemographic factors can be socioeconomic, ... race, ethnicity, and primary language. Growing evidence ...
    (Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
    (Date:7/23/2014)... HealthDay Reporter WEDNESDAY, ... overweight American children and teens look in the mirror ... officials reported Wednesday. "Being overweight or obese is ... pressure, high cholesterol and diabetes," said lead researcher Neda ... Disease Control and Prevention,s National Center for Health Statistics. ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 Inventor and ... From football games to the gas pump – sharing ... on Wednesday, July 30 at Noon. , With 24 ... has more patents than anyone in the General Assembly ... superimposed yellow line yard marker as seen on television, ...
    Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
    ... synthetic bone matrix offers hope for babies born with craniosynostosis, ... fuse too soon. Implants replacing some of the infant,s bone ... currently used to treat the condition. "The remarkable thing ... matrix changes what the cells around it do. Cells begin ...
    ... disease, stroke more likely for organ recipients with sleep ... News) -- Kidney transplant patients with sleep apnea are ... and stroke, Hungarian researchers say. , The study of ... moderate to severe sleep apnea, a rate similar to ...
    ... and costs, study finds , THURSDAY, Nov. 19 (HealthDay ... angiography is quicker, more accurate and much less expensive ... to moderate enzyme and EKG scores, according to a ... pain patients at 16 emergency rooms who were randomly ...
    ... 19 2009 has been a monumental year for ... from QUITPLAN Services, QuitCash Challenge, helped the 31-year-old Columbia ... The Challenge. Nearly 2,000 Minnesotans, including Doug, attempted to ... win the $5,000 grand prize. , On Thursday, November ...
    ... Official Statement by Teamsters General President Jim Hoffa ... Jim Hoffa issued the following statement today about the Senate ... health plans that will mean a huge middle-class tax hike ... would impose an excise tax on insurers for higher-cost health ...
    ... Nov. 19 Monogram Energy, Inc. ("Monogram") (Pink Sheets: ... of Triad Therapeutics, Inc. ("Triad"), which was effective as ... the Stock Purchase and Recapitalization Agreement, shareholders of Monogram ... exchange for approximately 95% ownership to the Triad shareholders ...
    Cached Medicine News:Health News:Bone implant offers hope for skull deformities 2Health News:Kidney Transplant, Sleep Disorder May Add Up to Trouble 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2
    ... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
    ... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
    ... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
    ... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
    Medicine Products: